Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Früh, M.; Peters, S.

doi:10.1016/j.ccell.2018.04.005

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Détails

Demande d'une copie

ID Serval

serval:BIB_FD1D595C2E3A

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Editorial

Collection

Publications

Institution

UNIL/CHUV

Titre

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Périodique

Cancer cell

Auteur⸱e⸱s

Früh M., Peters S.

ISSN

1878-3686 (Electronic)

ISSN-L

1535-6108

Statut éditorial

Publié

Date de publication

14/05/2018

Peer-reviewed

Oui

Volume

Numéro

Pages

791-793

Langue

anglais

Notes

Publication types: Journal Article ; Comment
Publication Status: ppublish

Résumé

In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.

Mots-clé

Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Genomics, Humans, Immunotherapy, Lung Neoplasms, Neoplasm Recurrence, Local

OAI-PMH

oai:serval.unil.ch:BIB_FD1D595C2E3A

DOI

10.1016/j.ccell.2018.04.005

Pubmed

29763618

Web of science

000432494500002

Création de la notice

17/05/2018 18:11